Skip to main content
Not investment advice. Educational platform. See Disclaimer.
OTC: LGNZZ

Ligand Pharmaceuticals, Inc.

Healthcare | Medical - Pharmaceuticals

No licensed closing price on file for LGNZZ. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$9.65

Ligand Pharmaceuticals, Inc. (OTC: LGNZZ) is a pharmaceutical company. Figures from SEC EDGAR; updated 2026-10-20 00:35 UTC.

What Ligand Pharmaceuticals, Inc. does

Ligand is a biopharmaceutical royalty company that acquires and creates royalty streams from drug development and commercial programs, generating cash flows without the infrastructure costs of traditional drug developers. The company invests through multiple structures including royalty purchases, company acquisitions with embedded royalties, development-stage financing, and ownership of platform technologies like Captisol and NITRICIL. Revenue comes primarily from royalties on partner-commercialized products, along with material sales and license fees.

Summarized from Ligand Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$9.65
Return on equity12.23%
Debt/equity1.16

Revenue, margins & earnings

FY2021 Net income: $57MFY2021 Taxes & interest: $47MFY2021 Operating costs: $138M$242MFY2021FY2022: net loss $33M on revenue $196M$196MFY2022FY2023 Revenue: $131M — margin split not shown (non-operating gains)$131MFY2023FY2024: net loss $4M on revenue $167M$167MFY2024FY2025 Revenue: $268M — margin split not shown (non-operating gains)$268MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
No insider transactions on file with the SEC for LGNZZ.
Source: SEC EDGAR · Last checked 2026-10-20
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Ligand Pharmaceuticals, Inc. do?

Ligand is a biopharmaceutical royalty company that acquires and creates royalty streams from drug development and commercial programs, generating cash flows without the infrastructure costs of traditional drug developers.

When did LGNZZ last file with the SEC?

Ligand Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 00:35 UTC. This page is also available as JSON at /api/data?ticker=LGNZZ and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LGNZZ and 5,000+ tickers.

Create a free account — keep LGNZZ
For your agent
GET /api/data?ticker=LGNZZ

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt